1855-23-8

Usage

Uses

Used in Pharmaceutical Industry:
5-cyclohexylsalicylic acid is used as a pharmaceutical agent for its potential anti-inflammatory and analgesic properties. It is being studied for its ability to alleviate pain and reduce inflammation, which could lead to the development of new drugs for treating various pain and inflammation-related conditions.
Used in Material Science:
5-cyclohexylsalicylic acid is used as a component in material science due to its unique molecular structure and properties. Its potential applications in this field are currently being explored, which may lead to the creation of new materials with specific characteristics.
Used in Organic Synthesis:
5-cyclohexylsalicylic acid is used as a building block in organic synthesis. Its distinct structure allows it to be a valuable intermediate in the synthesis of more complex organic compounds, contributing to the advancement of organic chemistry and the development of new chemical products.

InChI:InChI=1/C13H16O3/c14-12-7-6-10(8-11(12)13(15)16)9-4-2-1-3-5-9/h6-9,14H,1-5H2,(H,15,16)

Upstream product

• 323-87-5 4-hydroxybiphenyl-3-carboxylic acid 
• 1131-60-8 p-cyclohexylphenol 
• 89-55-4 5-bromosalicyclic acid 
• 89490-05-1 cyclohex-1-enylboronic acid 
• 107274-65-7 2-bromo-4-cyclohexyl-1-methoxybenzene 
• 69-72-7 salicylic acid 
• 108-93-0 cyclohexanol 
• 106596-75-2 5-cyclohexyl-2-methoxy-benzoic acid 
• 108-24-7 acetic anhydride 

Relevant academic research and scientific papers

Diflunisal Derivatives as Modulators of ACMS Decarboxylase Targeting the Tryptophan-Kynurenine Pathway

In the kynurenine pathway for tryptophan degradation, an unstable metabolic intermediate, α-amino-β-carboxymuconate-?-semialdehyde (ACMS), can nonenzymatically cyclize to form quinolinic acid, the precursor for de novo biosynthesis of nicotinamide adenine dinucleotide (NAD+). In a competing reaction, ACMS is decarboxylated by ACMS decarboxylase (ACMSD) for further metabolism and energy production. Therefore, the inhibition of ACMSD increases NAD+ levels. In this study, an Food and Drug Administration (FDA)-approved drug, diflunisal, was found to competitively inhibit ACMSD. The complex structure of ACMSD with diflunisal revealed a previously unknown ligand-binding mode and was consistent with the results of inhibition assays, as well as a structure-activity relationship (SAR) study. Moreover, two synthesized diflunisal derivatives showed half-maximal inhibitory concentration (IC50) values 1 order of magnitude better than diflunisal at 1.32 ± 0.07 μM (22) and 3.10 ± 0.11 μM (20), respectively. The results suggest that diflunisal derivatives have the potential to modulate NAD+ levels. The ligand-binding mode revealed here provides a new direction for developing inhibitors of ACMSD.

COMPOUNDS USEFUL FOR THE TREATMENT OF METABOLIC DISORDERS AND SYNTHESIS OF THE SAME

The present invention provides compounds of Formula (I): wherein variables X, Y, Z and R1 are as described herein. Some of the compounds described herein are glutamate dehydrogenase activators. The invention is also directed to pharmaceutical compositions comprising these compounds, uses of these compounds and compositions in the treatment of metabolic disorders as well as synthesis of the compounds.